Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Dermatofibrosarcoma protuberans].

O Sanmartín1, B Llombart, J A López-Guerrero

  • 1Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España. osanmartinj@gmail.com

Actas Dermo-Sifiliograficas
|April 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete Lymph Node Dissection vs Observation in Patients With Cutaneous Melanoma and Positive Sentinel Lymph Node Biopsy With High-risk Criteria: Multicenter Analysis in Hospitals in the Mediterranean Area.

Actas dermo-sifiliograficas·2026
Same author

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.

International journal of molecular sciences·2026
Same author

Clinical, Histopathologic, and Surgical Aspects of Dermatofibrosarcoma Protuberans on the Head vs Other Locations: Retrospective Single-center Case Series of 235 Tumors.

Actas dermo-sifiliograficas·2026
Same author

Utility of Dermoscopy in Preoperative Delineation of Basal Cell Carcinoma in Mohs Micrographic Surgery: A Prospective Single-centre Study of 98 Cases.

Actas dermo-sifiliograficas·2026
Same author

Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification.

Actas dermo-sifiliograficas·2025
Same author

Lacrimal Sac Cylindroma Hidden by a Basal Cell Carcinoma.

Journal of cutaneous pathology·2025
Same journal

Fingolimod-associated lymphomatoid papulosis.

Actas dermo-sifiliograficas·2026
Same journal

Demodicosis: update and treatment with laser and other light sources.

Actas dermo-sifiliograficas·2026
Same journal

New treatments for adult female acne.

Actas dermo-sifiliograficas·2026
Same journal

First regulations of the Spanish Society of Dermatology (1909).

Actas dermo-sifiliograficas·2026
Same journal

Long-hair FUE: advantages and disadvantages of the most recent technique in hair transplantation.

Actas dermo-sifiliograficas·2026
Same journal

Sunburns, Tanning, and Social Media: A Descriptive Study Among Spanish University Students.

Actas dermo-sifiliograficas·2026
See all related articles

Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. New targeted therapies show promise for advanced cases, improving outcomes where traditional treatments fall short.

Area of Science:

  • Oncology
  • Dermatology
  • Soft Tissue Neoplasms

Context:

  • Dermatofibrosarcoma protuberans (DFSP) is an intermediate-grade soft tissue neoplasm originating in the skin.
  • DFSP accounts for approximately 1.8% of soft tissue sarcomas and 0.1% of all cancers.
  • Localized treatment involves wide surgical excision or Mohs surgery; however, advanced or metastatic cases have a poor prognosis.

Purpose:

  • To review the challenges in treating locally advanced and metastatic Dermatofibrosarcoma protuberans.
  • To highlight the limitations of conventional chemotherapy and radiotherapy for DFSP.
  • To discuss the emergence of targeted therapies based on the COL1A1-PDGFB translocation.

Summary:

  • DFSP can invade deep structures, and metastatic cases, often following local relapses, have a survival rate under two years.

Related Experiment Videos

  • Locally advanced DFSP often requires neoadjuvant treatment to reduce tumor burden before surgery.
  • The identification of the COL1A1-PDGFB translocation has led to the development of PDGFB receptor antagonists.

    • Impact:

    • Targeted therapies offer new hope for patients with advanced or metastatic DFSP.
    • Understanding the molecular drivers of DFSP facilitates personalized treatment strategies.
    • Advances in DFSP treatment may improve survival rates and quality of life for affected individuals.